Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Impact · against what's priced in

Arrowhead Pharmaceuticals' plozasiran demonstrates strong Phase 3 efficacy in reducing triglycerides (79-81%) and pancreatitis events, including a 100% reduction in high-risk patients. This success significantly improves the probability of FDA approval for a broader indication via a supplemental NDA planned for 2026.

ARWR+0.80

No priced-in read yet

In context

Plozasiran met all primary and secondary endpoints in two Phase 3 trials, showing a 79-81% reduction in triglycerides and a 78% drop in pancreatitis events, providing a strong clinical basis for the planned 2026 sNDA submission.

Read from the article alone

• pharmaceuticals
• healthcare
• biotech
• ARWR
• clinical trials
• drug efficacy
• fda
• hypertriglyceridemia
• pancreatitis
• regulatory approval

Search tags